

Special Issue

New Insights in Aneurysmal Subarachnoid Hemorrhage Pathogenesis and Its Impact on Outcome and Treatment

Message from the Guest Editors

Aneurysmal subarachnoid hemorrhage is a complex disease following intracranial aneurysm rupture and leading to a protracted clinical course due to the circulating blood products in the cerebrospinal fluid. Although many factors influencing the overall outcome are known, the specific impact of a specific aneurysm morphology, anatomic location and/or size, as well as patient sex are less frequently addressed as factors influencing the overall patient outcome. We aim to explore how the neuro-anatomical factors of a ruptured intracranial aneurysm influence treatment decisions, clinical course and outcome of patients with aneurysmal subarachnoid hemorrhage. Research areas may include:

- preclinical/clinical studies on aneurysm morphology in aneurysmal subarachnoid hemorrhage models, especially within the context of pathogenesis mechanisms and translational research;
- clinical cohort studies addressing risk-factor and predictive models with an emphasis on aneurysm morphology, location, size and patient-specific factors (e.g., sex or age);
- and preclinical/clinical studies where neuro-anatomical and morphological factors are used for specific open-vascular or endo-vascular treatment.

Guest Editors

Dr. Michel Roethlisberger

Dr. Basil Grüter

Dr. Isabel Hostettler

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/156881

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).